Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Hematological malignancies, including cutaneous T-cell lymphoma (CTCL), show promise with combined JAK/STAT and HDAC inhibitors.
• Investigating the efficacy of ruxolitinib (JAK1/2 inhibitor) and resminostat (HDAC inhibitor) in CTCL models is crucial.

Purpose of the Study:

• To evaluate the in vitro efficacy of combining ruxolitinib (JAK1/2 inhibitor) with resminostat (HDAC inhibitor) in CTCL.
• To assess the impact of this drug combination on CTCL cell proliferation, apoptosis, and key signaling pathways.

Main Methods:

• MyLa (MF) and SeAx (SS) CTCL cell lines were treated with non-toxic concentrations of ruxolitinib and/or resminostat.
• Cytotoxicity, proliferation, and apoptosis were measured using MTT, BrdU/7-AAD, and Annexin V/PI assays.
• Multi-pathway analysis investigated effects on JAK/STAT, Akt/mTOR, and MAPK signaling.

Main Results:

• The drug combination demonstrated significant cytotoxicity and inhibited proliferation in both MyLa and SeAx cell lines.
• Combined treatment synergistically induced apoptosis in CTCL cells (Combination Index < 1).
• The combination suppressed phosphorylation of STAT3, Akt, ERK1/2, and JNK signaling pathways in CTCL cells.

Conclusions:

• The combination of JAK inhibitors and HDAC inhibitors exhibits potent anti-tumor activity in CTCL cell lines.
• This synergistic drug combination represents a promising novel therapeutic strategy for CTCL patients.